Sanara MedTech Inc. (NASDAQ:SMTI) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Sanara MedTech Inc. (NASDAQ:SMTI) have earned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $34.00.

A number of research analysts have weighed in on SMTI shares. Wall Street Zen raised shares of Sanara MedTech from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 4th. Lake Street Capital began coverage on shares of Sanara MedTech in a report on Wednesday, April 15th. They set a “buy” rating and a $32.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sanara MedTech in a research report on Tuesday, April 21st. Freedom Capital raised shares of Sanara MedTech to a “strong-buy” rating in a research note on Wednesday, June 17th. Finally, Zacks Research upgraded Sanara MedTech from a “strong sell” rating to a “hold” rating in a report on Wednesday, June 10th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its stake in Sanara MedTech by 351.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock valued at $48,000 after buying an additional 1,171 shares during the last quarter. Lazard Asset Management LLC boosted its stake in shares of Sanara MedTech by 63,100.0% during the 2nd quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock worth $89,000 after buying an additional 3,155 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Sanara MedTech by 44.1% in the 3rd quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock valued at $101,000 after acquiring an additional 973 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Sanara MedTech by 78.1% in the 4th quarter. Wells Fargo & Company MN now owns 3,322 shares of the company’s stock valued at $78,000 after acquiring an additional 1,457 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of Sanara MedTech by 14.9% in the first quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock valued at $115,000 after acquiring an additional 483 shares during the last quarter. Institutional investors own 8.10% of the company’s stock.

Sanara MedTech Stock Performance

NASDAQ:SMTI opened at $23.82 on Monday. The company has a debt-to-equity ratio of 6.59, a current ratio of 2.28 and a quick ratio of 2.05. The business’s 50-day simple moving average is $22.28 and its 200-day simple moving average is $21.06. Sanara MedTech has a fifty-two week low of $16.05 and a fifty-two week high of $35.95. The stock has a market capitalization of $218.19 million, a PE ratio of -6.32 and a beta of 1.18.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.